Supernus Pharmaceuticals Income from Continuous Operations 2011-2024 | SUPN
Supernus Pharmaceuticals income from continuous operations from 2011 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Supernus Pharmaceuticals Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$1 |
| 2022 |
$61 |
| 2021 |
$53 |
| 2020 |
$127 |
| 2019 |
$113 |
| 2018 |
$111 |
| 2017 |
$57 |
| 2016 |
$91 |
| 2015 |
$14 |
| 2014 |
$-11 |
| 2013 |
$-92 |
| 2012 |
$-46 |
| 2011 |
$-23 |
| 2010 |
$-39 |
Supernus Pharmaceuticals Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-06-30 |
$20 |
| 2024-03-31 |
$0 |
| 2023-12-31 |
$1 |
| 2023-09-30 |
$-16 |
| 2023-06-30 |
$-1 |
| 2023-03-31 |
$17 |
| 2022-12-31 |
$25 |
| 2022-09-30 |
$2 |
| 2022-06-30 |
$8 |
| 2022-03-31 |
$26 |
| 2021-12-31 |
$2 |
| 2021-09-30 |
$22 |
| 2021-06-30 |
$24 |
| 2021-03-31 |
$6 |
| 2020-12-31 |
$31 |
| 2020-09-30 |
$40 |
| 2020-06-30 |
$35 |
| 2020-03-31 |
$22 |
| 2019-12-31 |
$33 |
| 2019-09-30 |
$29 |
| 2019-06-30 |
$33 |
| 2019-03-31 |
$18 |
| 2018-12-31 |
$26 |
| 2018-09-30 |
$28 |
| 2018-06-30 |
$31 |
| 2018-03-31 |
$26 |
| 2017-12-31 |
$14 |
| 2017-09-30 |
$16 |
| 2017-06-30 |
$17 |
| 2017-03-31 |
$10 |
| 2016-12-31 |
$14 |
| 2016-09-30 |
$62 |
| 2016-06-30 |
$10 |
| 2016-03-31 |
$5 |
| 2015-12-31 |
$7 |
| 2015-09-30 |
$4 |
| 2015-06-30 |
$2 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$4 |
| 2014-09-30 |
$-2 |
| 2014-06-30 |
$3 |
| 2014-03-31 |
$-16 |
| 2013-12-31 |
$-22 |
| 2013-09-30 |
$-24 |
| 2013-06-30 |
$-27 |
| 2013-03-31 |
$-18 |
| 2012-12-31 |
$-14 |
| 2012-09-30 |
$-13 |
| 2012-06-30 |
$-10 |
| 2012-03-31 |
$-9 |
| 2011-12-31 |
$6 |
| 2011-09-30 |
$-10 |
| 2011-06-30 |
$-9 |
| 2011-03-31 |
$-10 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.771B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
